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EXTENDED EXPERIMENTAL PROCEDURES
Generation of Spicigfp/+ Mice
The targeting construct was prepared using the Gateway recombination system (Invitrogen). To construct pENTR loxFRT rNEO
IRES-EGFP, a floxed PGK (phosphoglycerate kinase promoter-neomycin phosphotransferase)-neoR gene cassette (1,982 bp)
was excised from the pLNTK targeting vector using SalI and XhoI. After incubation with Easy-A cloning enzyme (Stratagene) and
dNTPs to generate 30-dideoxy adenine overhangs, this PGK–neoR cassette was ligated into the multiple cloning site of pGEM
T-Easy (Promega). The resulting 2,022 bp PGK–neoR gene cassette was released using NotI and ligated into the 2,554 bp backbone
of NotI digested pENTR lox-Puro. Flippase Recognition Target (FRT) sites were sequentially inserted at the SacI and HindIII sites us-
ing DNA fragments generated by following annealing oligonucleotides: SacII-FRT-A (GAAGTTCCTATTCCGAAGTTCCTATTCTC
TAGAAAGTATAGGAACTTCCGC) and SacII-FRT-B (GGAAGTTCCTATACTTTCTAGAGAATAGGAACTTCGGAATAGGAACTTCGC);
or HindIII-FRT-A (AGCTTGAAGTTCCTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC) and HindIII-FRT-B (AGCTGAAG
TTCCTATACTTTCTAGAGAATAGGAACTTCGGAATAGGAACTTCA).
IRES2-EGFP was excised from pIRES2-EGFP (BD Biosciences Clontech) using BamHI and Afl II, and blunted using VentR DNA
Polymerase (New England BioLabs). This fragment was inserted into the pENTR loxFRT rNEO, which was digested with ScaII and
blunted using VentR DNA polymerase. To construct pENTR-50arm, the 50arm was generated by PCR from genomic DNA using
the following oligonucleotides which contain attP4 and attB1R sites: GGGGACAACTTTGTATAGAAAAGTTGTCTAACTCACAGAA
ACCCAGTGTTT, and GGGGACTGCTTTTTTGTACAAACTTGGAATTGAAGAGTCTTGGGTTGCGGA. The attP4-attB1R PCR frag-
ment was ligated into pDONR(P4-P1R) plasmid (Invitrogen) by BP recombination reaction. To construct pENTR-30arm, the 30arm
was generated by PCR from genomic DNA using the following 12 oligonucleotides which contain attb2 and attB3 sites: GGGGAC
AGCTTTCTTGTACAAAGTGGGTCAGTCGGCATTTTTTTAAAAA and GGGGACAACTTTGTATAATAAAGTTGCCTATGCTGGTCTCC
CCCACATTTT. The attb2-attB3 PCR fragment was ligated into pDONR (P2-P3) plasmid (Invitrogen) by BP recombination reaction.
The LR recombination reaction was performed to generate the final targeting construct by using these three entry clones.
Antibodies
The following antibodies were used for flow cytometry, cell sorting, immunohistochemistry, and western blots as noted. APC anti-
F4/80 (MF48005, Invitrogen), Pacific Blue anti-F4/80 (MF48028, Invitrogen), PE-Cy7 anti-CD11b (25-0112-82, eBioscience),
eFluor450 anti-MHC-II (48-5321-82), PE anti-TremL4 (143303, BioLegend), eFluor450 anti-VCAM1 (48-1061-80), biotin anti-
VCAM1 (13-1061-82, eBioscience), FITC anti-VCAM1 (11-1061-82, eBioscience), PE anti-Ly6G (551461, BD Pharmingen), V450
anti-Ly6C (560594, BD Biosciences), PerCP-Cy5.5 anti-Ter119 (560512, BD Biosciences), biotin anti-Ter119 (13-5921-82,
eBioscience), anti-GFP (A11122, Invitrogen), FITC anti-CD45.1 (553775, BD Pharmingen), APC eFluor780 anti-CD45.1 (47-0453-82,
eBioscience), PE-Cy7 anti-CD45.1 (25-0453-82, eBioscience), PerCP-Cy5.5 anti-CD45.1 (45-0453-82, eBioscience), APC eFluor780
anti-CD45.2 (47-0454-82, eBioscience), PerCP-Cy5.5 anti-CD45.2 (45-0454-80, eBioscience), eFluor450 anti-CD45R (48-0452-82,
eBioscience), APC anti-CD3e (553066, BD Pharmingen), APC anti-human CD4 (MHCD0427, Invitrogen or 300514, BioLegend), PE
anti-human CD4 (MHCD0404, Invitrogen), anti-Bach1 (AF5777, R&D Systems), anti-tubulin (53463, Cell Signaling), HRP anti-goat,
biotin anti-CD68 (ABD Serotec), APC anti-CD169 (ABD Serotec), 488 anti-goat IgG (A11055, Invitrogen), Alexa Fluor 647 streptavidin
(1024071, Invitrogen) and PE-Cy7 streptavidin (557598, BD Pharmingen). 7-AAD (51-6898, BD Biosciences) was used to label live
cells for flow cytometry-based studies. DAPI (1140028, Invitrogen) was used to label nuclei on frozen sections.
Chemicals and Drugs
The following chemicals were used for in vitro and in vivo experiments as indicated: heme (Hemin, 51280-1G, Sigma), bilirubin (B584-
9, Frontier Scientific), biliverdin (Biliverdin hydrochloride, B655-9, Frontier Scientific), chromiummesoporphyrin (Cr(III) Mesoporphyr-
in(IX) Chloride, CrM459, Frontier Scientific), phenylhydrazine (Phenylhydrazine hydrochloride, 114715-5G, Sigma), Nr1d1 agonist
(GSK4112, Tocris Biosciences), LXR agonist (GW3965, Sigma), Ppar-g agonist (Pioglitazone hydrochloride, 4124, Tocris Biosci-
ence), RXR agonist (Retinoic acid, R2625, Sigma), and deferoxamine (Deferoxamine mesylate salt, D9533-1G, Sigma). The Hemin
stock solution was prepared at 25 mg/ml in 0.15 MNaCl containing 10%NH4OH (vehicle) and stored at20C. The phenylhydrazine
solution was prepared fresh at 10 mg/ml in 1X PBS (sterile, pH 7.4). The chromium mesoporphyrin stock solution was prepared at
75 mM concentration in 50 mM Na2CO3 solution. For intraperitoneal treatment, stock Crmp was diluted in sterile 1X PBS prior to
injections. Cycloheximide (Sigma-Aldrich). MG132 (Sigma-Aldrich). OCT compound (4583, Tissue-Tek). CAS blocking reagent
(008120, Invitrogen).
Cloning and Retrovirus Infection
The cDNAs used in this study were amplified frommouse splenocyte RNA using Superscript III (Invitrogen). The cDNAs and the cor-
responding primers are as follows: Spic cDNA was amplified with forward primer 50-AGAGATCTGCAACCCAAGACTCTTCAATTC-30
and reverse primer 50-CCACTCGAGAGGCAAGAAGCTGGGGTCA-30; Tcfec cDNA was amplified with forward primer 50-CCGGA
GTTCTATGAGCAAGC-30 and reverse primer 50-TGCGGCTTACAACTCATCAC-30; Bach1 cDNA was amplified with forward primer
50-TGTGATCACGGTCGATGACAGTGAGAAGCATG-30 and reverse primer 50 – TAGTCGACTGCCCGTGGGGTTTACTCGT – 30.
Aforementioned cDNAs were cloned into BglII and XhoI digested GFP-RV retroviral constructs to generate the respective retroviral
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overexpression vectors that were next transfected into Phoenix-E cells as described previously (Kanbe and Zhang, 2004; Sedy et al.,
2005), and viral supernatants were collected 2 days later. BM cells were infected with viral supernatants in the presence of 2 mg/ml
polybrene by spin infection at 2,500 rpm for 45 min.
Quantitative Real-Time PCR
Total RNA and cDNA were prepared with the RNeasy Mini Kit (QIAGEN) and Superscript III reverse transcriptase (Invitrogen). Real-
time PCR analysis was performed using ABI SYBR Green master mix and StepOnePlus Real-Time PCR system (Applied Bio-
systems).The PCRconditionswere 10min at 95C followed by 40 two-step cycles consisting of 15 s at 95Cand 1min at 60C. Primer
sequences used to evaluate relative gene expression were followings: Spic forward, 50 – TCCGCAACCCAAGACTCTTCAA – 30; Spic
reverse, 50 – GGGTTCTCTGTGGGTGACATTCCAT – 30; HPRT forward, 50-TCAGTCAACGGGGGACATAAA-30; and HPRT reverse,
50-GGGGCTGTACTGCTTAACCAG-30.
Cell Preparation
BMcells were harvested by flushing the femur and tibia with Iscove’smodified Dulbecco’smedium (IMDM)with 10%FCS. Peritoneal
cells were harvested by injecting and collecting IMDM + 10% FCS into the peritoneal cavity of euthanized mice. Solid organs were
harvested and digested in 0.25 mg/ml collagenase B (Roche) and 30 U/ml DNase I (Sigma-Aldrich) for 30 min with constant agitation
at 37C. Cells collected from the BM, peritoneum, and solid organs were treated with ACK lysis buffer to remove erythrocytes, filtered
through 80 mm filter, and resuspended in appropriate buffer.
Flow Cytometry and Cell Sorting
For flow cytometry or cell sorting, single-cell suspension in MACS buffer (0.5% BSA and 2 mM EDTA in PBS at pH 7.2) were blocked
with anti-CD16/32 (clone 2.4G2; BD) for 5-10 min at 4C followed by labeling with the indicated antibodies. All flow cytometry data
were collected on a FACS Canto (BD Biosciences) and analyzed with FlowJo software (Tree Star). Cell sorting (post-sort purity >
90%) was carried out using the FACSAria II (BD Biosciences). To obtain purified Spic-EGFP and Spic-EGFP+ monocytes for micro-
array analysis, spleens were prepared from Spicigfp mice as described above and were first negatively selected for CD4, CD8, and
B220 by MACS (Miltenyi Biotech) purification using the respective microbeads. Negatively selected splenocytes were then stained
with anti-CD11b and anti-Ly6C and sorted. Purified RPM were obtained by staining splenocytes with anti-F4/80 and sorting for
F4/80hi Spic-EGFPhi cells.
Microarray Analysis
For expression analysis of splenic monocytes, pre-RPM, and RPM, total RNA was isolated from cells using RNeasy Kit (QIAGEN).
Biotinylated antisense cRNA was generated using a two-cycle target preparation kit (Affymetrix). After fragmentation, cRNA was
hybridized to Affymetrix Mouse Genome 430 2.0 arrays. Data were normalized and expression values were modeled using ArrayStar
4 (DNASTAR).
For expression analysis of heme and vehicle exposedGM-CSF cultures of BM cells (WT,Spicigfp/igfp, andBach1/), total RNAwas
isolated from cells using RNeasy Kit (QIAGEN). RNA was amplified, labeled, and fragmented using the NuGEN PicoSL system and
hybridized to the Affymetrix MouseGene 1.0 ST arrays. Data were normalized and expression values weremodeled using ArrayStar 4
(DNASTAR).
Histology
Tissue was fixed in 4% buffered formalin, cryoprotected with 30% sucrose, and frozen in OCT compound. 6-8 mm sections of the
frozen tissue were prepared and blocked with the CAS blocking reagent. Sections were then stained with indicated antibodies
following standard immunohistochemistry protocols. Epifluoroscence microscopy was performed using an AxioCam MRn micro-
scope equipped with an AX10 camera (Carl Zeiss). Monochrome images were acquired with AxioVision software (Carl Zeiss) and
subsequent color balancing and overlaying was performed with ImageJ software (National Institutes of Health).
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Figure S1. Generation of Spicigfp/+ Mice, Related to Figure 1
(A) The endogenous Spic locus (top), Spic-Ires-Egfp targeting vector (middle), and the correctly targeted Spic loci (bottom) are shown. Coding (black) and
noncoding (open) exons are represented as numbered boxes. BamHI digestion of the endogenous locus generates a restriction fragment of 11 kb detected by the
50probe, and EcoRV digestion of the endogenous locus generates a restriction fragment of 7.5 kb detected by the 50probe and 30probe. In clones retaining the
neomycin resistance cassette, the 50 probe detects a 12 kb fragment, and the 30probe detects a 5.4 kb fragment. B, BamHI; RV, EcoRV; neo, neomycin resistance
cassette.
(B) Shown is a Southern analysis using 30 probe shown in (A) that hybridizes to EcoRV-digested genomic DNA from Spic+/igfp mice or Spic+/+ mice.
(C) Splenocytes from Spic+/+ and Spicigfp/igfpwere stained with F4/80, MHC-II, and CD11b. Shown are the flow cytometry plots with indicated markers. Numbers
represent percentage of cells within indicated gate. Data represent more than 3 experiments with 2 or more mice per group.
(D) Shown is the quantitative real-time PCR analysis of Spic transcripts isolated from EGFP+ and EGFP splenocytes purified by cell sorting from Spicigfp/+mice.
Expression was normalized to Hprt expression and is presented relative to the expression in EGFP+ cells. Data are combined from three independent
experiments.
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Figure S2. Spic Expression Is Specific to RPM and BMM and Is Required for Their Development, Related to Figure 1
(A) Cells from liver (top), peritoneal cavity (middle), and lung (bottom) were harvested from Spic+/+ and Spicigfp/igfp mice and stained for CD45 and F4/80. Shown
are the flow cytometry plots for the indicated markers after gating for CD45 expression.
(B–E) BM cells and splenocytes from Spic+/+ and Spicigfp/igfp were stained for CD11b (B), MHC-II (C), VCAM1 (D), and TREML4 (E), as indicated in the flow
cytometry plots.
(F, left) Shown is the single-color histogram for Zbtb46-EGFP expression in CD11chi dendritic cells and F4/80hi BMM and RPM from Zbtb46gfp/+mice. (F, middle)
Shown is the single-color histogram for Spic-EGFP expression in splenic RPM (F4/80hiCD11blo) and splenic dendritic cells (CD11chi MHC-IIhi). (F, right) shown is
the single-color histograms for Spic-EGFP expression in TREML4-expressing splenic macrophages and TREML4-expressing splenic dendritic cells.
(G) Cells from the peritoneal cavity (top) and liver (bottom) were collected from Spic+/+ and Spic/ mice and stained for F4/80 and VCAM1. Shown are the flow
cytometry plots for the indicated markers. Right: absolute number of F4/80hi peritoneal macrophages (bars: mean + SD, n = 3). Numbers in the flow cytometry
plots represent percentage of cells within indicated gate.
(H) Blood was collected by tail bleeding in EDTA tubes (Microvette, Sarstedt) on the indicated days (x axis) after treatment with 200 ml of PBS or PDZ (2 mg in PBS)
on day 0. CBC was performed and the hemoglobin concentration (gram/deciliter) is plotted on the y axis. Differences in hemoglobin levels are not significant (p >
0.05, unpaired t test) at any time point. All data in this figure are representative of two or more experiments with at least twomice per group. PEC, peritoneal cells.
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Figure S3. RPM-Associated Transcription Factors Do Not Regulate Spic Expression, Related to Figure 2
(A) GM-CSF cultures of Spicigfp/igfpBM cells were infected with retroviral vectors expressing only humanCd4 (Empty-RV), expressing Spic and humanCd4 (Spic-
RV), and expressing the transcription factor Tcfec and human Cd4 (Tcfec-RV). Seven days after infection, cells were harvested and stained for 7AAD and hCD4.
Shown are the flow cytometry plots with the indicated markers. 7AAD live cells (column 1) gated for human CD4 expression (column 2) represent live cells
infected with the respective retrovirus. These 7AADhCD4+ cells were then analyzed for EGFP expression as shown in the single-color histogram on right.
Numbers in the flow cytometry plots represent percentage of cells within indicated gate.
(B) GM-CSF cultures of Spicigfp/igfp BM cells were treated with the Nr1d1 agonist GSK4112 (10 mM). Cells were collected after 8 days and analyzed for EGFP
expression after gating out autofluorescence as shown is the single-color histogram.
(C) GM-CSF cultures of Spicigfp/igfp BM cells were treated with LXR agonist GW3965 hydrochloride (1 mM), Ppar-g agonist pioglitazone hydrochloride (1 mM), or
vehicle after 4 days in culture. Cells were collected 5 days after treatment and analyzed for EGFP as shown in the single-color histogram.
(D) GM-CSF cultures of Spicigfp/igfp BM cells were treated with RXR agonist retinoic acid (10 mM). Cells were harvested after 10 days and analyzed for EGFP as
shown in the single-color histogram.
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Figure S4. Heme, but Not Heme Metabolites, Induces Spic Expression in Macrophages Generated In Vitro, Related to Figure 2
(A) BM cells from Spicigfp/igfpwere cultured in 20 ng/ml of GM-CSF, G-CSF, or M-CSF. After 5 days, heme (40 mM) or vehicle was added to the culture. Cells were
harvested 2 days after treatment and stained with F4/80. Shown are flow cytometry plots with the indicated markers.
(B) GM-CSF cultured Spicigfp/igfpBMcells were treatedwith heme (40 mM)with or without the iron chelator deferoxamine (20 mM) at the onset of culture. Cells were
harvested after 10 days and stained with F4/80. Shown are the flow cytometry plots with the indicated markers.
(C) GM-CSF cultured Spicigfp/igfp BM cells were treated with heme (30 mM) with or without the HO1 inhibitor Crmp (10 mM) at the onset of culture. Eight days later,
the cells were collected and analyzed for EGFP expression. Numbers in the flow cytometry plots represent percentage of cells within the indicated gate. Data in
this figure are representative of two or more experiments with at least two mice or samples in each group.
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Figure S5. Heme Induces Pre-RPM In Vivo, Related to Figure 3
(A) Cells from the BM (top) and peritoneal cavity (bottom) were harvested from WT, Spicigfp/igfp, and Ho1/Spicigfp/igfp mice and stained with F4/80 and CD11b.
Shown are the flow cytometry plots with the indicated markers.
(B, top) Spicigfp/igfp and WT mice were treated with 200 ml intraperitoneal PBS or PDZ (2 mg in PBS) three times, each treatment 48 hr apart. 12 hr after the last
treatment, BM cells were harvested and stained for CD11b as shown in the flow cytometry plots. (B, bottom) Wild-type and Spicigfp/igfp mice were treated
intraperitoneally with 200 ml of PBS or heme (0.5 mg in PBS) on three consecutive days. 24 hr after the last treatment, BM cells were harvested and stained for
CD11b. Shown are the flow cytometry plots with the indicated markers.
(C) Splenocytes were harvested from 1-month-old and 2-month-oldHo1/Spicigfp/igfpmice. Cells were stained with F4/80. Shown is the flow cytometry plot with
the indicated markers.
(D) Splenocytes from Ho1/ Spicigfp/igfp mice (left), Spicigfp/igfp mice treated with PDZ (middle), and Spicigfp/igfp mice treated with heme (right) were stained for
CD11b and TREML4. Shown are the flow cytometry plots displaying TREML4 expression on CD11bhiEGFP+ (red) and CD11bhiEGFP (blue) cells. Numbers in the
flow cytometry plots represent percentage of cells within the indicated gate. All data in this figure is representative of two or more experiments with at least two
mice or samples per group.
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Figure S6. Monocytes Give Rise to Pre-RPM and RPM in the Presence of Heme, Related to Figure 4
(A) Monocytes were purified by MACS-based depletion of CD3+, B220+, and Ly6G+ cells followed by MACS-based enrichment for CD11b+ cells from CD45.2+
C57BL/6 splenocytes. Recipient CD45.1+ C57BL/6 mice were conditioned with PDZ or PBS treatment prior to transfer with about 63 106 purified monocytes via
tail vein injection. Recipient splenocytes were harvested 4 days after monocyte transfer and stained for Ter119, 7AAD (vital dye), CD45.2, CD45.1, F4/80, VCAM1,
and CD11b. Shown are the flow cytometry plots with the indicated markers demonstrating the presence of F4/80hiVCAMhi RPM-like donor cells selectively
among splenocytes of hosts experiencing hemolysis (PDZ treated).
(B) Shown is the single-color histogram displaying the expression of CD11b in donor-derived monocytes in the presence (red) or absence (blue) of hemolysis.
Numbers in the flow cytometry plots represent percentage of cells within indicated gate.
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Figure S7. Pre-RPMs Are Intermediates between Monocytes and RPM, Related to Figure 4
(A) Splenocytes from Spicigfp/+ mice were stained for F4/80, CD11b, and Ly6C and sorted for Spic-EGFP monocytes (CD11bhiLy6C+ Spic-EGFP), pre-RPM
(CD11bhiLy6C+ Spic-EGFP+), and RPM (F4/80hiCD11bloSpic-EGFP hi). RNA was extracted from the sorted cells and gene expression analysis carried out using
the Affymetrix expression platform. Gene expression values were normalized and analyzed using ArrayStar 4. Genes withR20-fold difference between EGFP
monocytes and RPM were selected. Shown are the expression levels (y axis) of the selected genes (x axis) in the three sorted populations.
(B) WT mice were treated once with 200 ml of PBS or PDZ (2 mg in PBS). Splenocytes were harvested after one day (left) or 4 weeks later (right). Harvested
splenocytes were stained with F4/80 and CD11b. Shown is the flow cytometry plots with the indicated markers. Numbers represent percentage of cells within
indicated gate.
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